// App-Quantinova.ai

INFO29 : A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)

Researchers

Presenter

  • L Heerspink HiddoJan

Principal Investigators

  • Kohan DonaldE

  • Lafayette RichardA

  • Levin Adeera

  • Perkovic Vlado

  • Zhang Hong

  • King AndrewJ

  • Glicklich Alan

  • Barratt Jonathan

Medical Centers

  • University Medical Center Groningen, Nijmegen, Netherlands

  • University of Utah, Salt Lake City, Utah, United States

  • Stanford Stanford California United States

  • The University of British Columbia Faculty of Medicine Vancouver British Columbia Canada

  • University of New South Wales Faculty of Medicine Sydney New South Wales Australia

  • Chinook Therapeutics Seattle Washington United States

  • University of Leicester Medical School Leicester Leicester United Kingdom

Locations

  • Netherlands

  • United States

  • Canada

  • Australia

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Nephrology

  • Urology

Disease

  • Primary glomerulonephritis

  • Microvascular complications of diabetes 1

  • End stage renal disease

  • Chronic kidney disease

  • Glomerulonephritis

  • IgA nephropathy

  • Type 2 diabetes mellitus

  • Renal disease

  • Albuminuria

  • Diabetes

Biomarkers

  • Cluster of differentiation 79A

  • Creatinine

Drug/Treatment

  • atrasentan

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved